Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

3 Downloads (Pure)
OriginalsprogEngelsk
TidsskriftCancer Communications
Vol/bind43
Udgave nummer6
Sider (fra-til)720-725
ISSN2523-3548
DOI
StatusUdgivet - jun. 2023

Bibliografisk note

Funding Information:
This research was funded in part by grants from the Danish Cancer Society (to Henrik J. Ditzel), Health Insurance “Denmark” (to Henrik J. Ditzel), Academy of Geriatric Cancer Research (AgeCare) (to Henrik J. Ditzel), and Pink Tribute (to Henrik J. Ditzel).

Citationsformater